In a report released today, Serge Belanger from Needham maintained a Buy rating on Heron Therapeutics (HRTX – Research Report), with a price target of $10.00. The company’s shares closed last Friday at $4.67.
According to TipRanks, Belanger is a 4-star analyst with an average return of 5.8% and a 46.76% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Heron Therapeutics, and Liquidia Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Heron Therapeutics with a $7.75 average price target.
See the top stocks recommended by analysts >>
HRTX market cap is currently $479.3M and has a P/E ratio of -2.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
Read More on HRTX:
